Share Name Share Symbol Market Type Share ISIN Share Description
Shire Plc LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.50p +0.20% 3,832.00p 3,837.00p 3,838.50p 3,847.00p 3,801.00p 3,818.00p 1,771,343 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9,229.1 393.7 34.8 120.3 22,709.34

Shire Share Discussion Threads

Showing 2401 to 2424 of 2425 messages
Chat Pages: 97  96  95  94  93  92  91  90  89  88  87  86  Older
DateSubjectAuthorDiscuss
22/9/2017
19:59
Not too bad for mine up almost 1% , mainly thanks to a big leap in DOM , one of my largest holdings.
philanderer
22/9/2017
17:39
Bad week for the portfolio I'm afraid. Up 0.1% Vs FTSE350 up 1.1% Mainly caused by this and Spire - both of which I believe are being played with and have been hammered unfairly. Spire in particular and looks like may be bought out in the coming days. Not in tobacco or alcohol BTW.
justiceforthemany
22/9/2017
17:18
Justice, I'd add Imperial Brands to that list ....I do hold 😉
philanderer
22/9/2017
16:13
GBP plummeting vs the dollar yet the usual BS and tricks here by MM's holding the share price back - UNregulated market +++
justiceforthemany
22/9/2017
15:44
My Top 5 Takeover targets for 2017-18 *SHIRE *SPIRE HEALTHCARE GROUP ITV HIKMA PHARMACEUTICALS VECTURA GROUP
justiceforthemany
22/9/2017
15:42
Broad Value Outlook In aggregate, Shire currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Shire a solid choice for value investors, and some of its other key metrics make this pretty clear too. For example, the PEG ratio for Shire is just 0.8, a level that is far lower than the industry average of 1.4. The PEG ratio is a modified PE ratio that takes into account the stock's earnings growth rate. Clearly, SHPG is a solid choice on the value front from multiple angles
justiceforthemany
22/9/2017
15:41
http://www.nasdaq.com/article/is-shire-plc-shpg-a-suitable-value-stock-cm848974 PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock's current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole. On this front, Shire has a trailing twelve months PE ratio of 11
justiceforthemany
22/9/2017
14:20
Dead cat bounce towards to low I reckon. Pish.
mbmiah
22/9/2017
11:46
Well that's a nice surprise. 😆
philanderer
22/9/2017
07:21
Should see 3750p today the way the ftse futures are pointing LONDON (Alliance News) - Stock prices in London are expected to open lower on Friday, as tensions between the US and North Korea heightened once again following US President Donald Trump's United Nations speech and latest US sanctions, with attention to turn later to the UK prime minister's Brexit speech in Italy.
philanderer
22/9/2017
01:23
I think it is just retesting the 36.00 level, from where IMO the trend will reverse.
andyj
21/9/2017
22:07
Swe, I doubled up around these levels too. At least we don't think the share price will be going much lower from here. I'd like to see us push above 4100 on the next upswing.
ruethewhirl
21/9/2017
21:08
I'd take 5000p , in fact I'd take 4800p
philanderer
21/9/2017
18:51
As I said before the CEO gave a long interview with the FT a couple of months ago about how 'fed up' he was with the share price and how he felt the market was undervaluing the company. At the time the share price was 4400p. The share price is now 3800p and has been down to 3600p. Competition concerns are vague and unsubstantiated at the moment - only those 'in the know' truly know what is going on behind the scenes. Brokers continue to target as high as 6000p - they are pretty hopeless but this is a huge disparity with the current share price I guess this is what they feel Shire would be worth if someone bid. If he really is as fed up as he seems I doubt he would turn down an offer around 5000p this time. As for GBP vs USD funny how Shire gets hammered more than its peers who also have large earnings in USD.
justiceforthemany
21/9/2017
11:27
thanks for that justice. again I just cant fathom the poor performance of the share price relative to peers. I doubled up at 3820 so am now averaging 4500. still a way off that!
swedeee
21/9/2017
09:29
Phil, just wonder if the market wants to see the next update before the share price can possibly reverse the downtrend.
essentialinvestor
21/9/2017
06:42
Futures flat now , not very hopeful for SHP today, what's new. :-S
philanderer
20/9/2017
21:59
https://seekingalpha.com/article/4106302-shire-shpg-presents-morgan-stanley-global-healthcare-conference-transcript Very positive commentary I'd say and 'all options are on the table' including a sale. I reckon the CEO is fed up with this share price and will sell up soon.
justiceforthemany
20/9/2017
21:58
Shire plc (NASDAQ:SHPG) and Japan licensee Shionogi & Co. (OTCPK:SGIOF) announce positive results in a Japan-based Phase 3 clinical trial evaluating INTUNIV (guanfacine hydrochloride prolonged release) in adults with attention deficit hyperactivity disorder (ADHD), the first such study conducted anywhere in the world. Shionogi intends to advance development and file an marketing application in Japan for the indication. It was approved there in March to treat children and adolescents with ADHD (ages 6 - 17). https://seekingalpha.com/news/3296546-shires-intuniv-successful-late-stage-study-adult-adhd
justiceforthemany
20/9/2017
21:57
Shire Stock Slump Offers Investment Opportunity With Strong Upcoming Catalysts https://seekingalpha.com/article/4103358-shire-stock-slump-offers-investment-opportunity-strong-upcoming-catalysts Shire PLC filed marketing application for its dry eye medication in Europe. The company may spin off its neuroscience unit, unlocking value for shareholders. Shire reported strong results for Phase 3 study of Hereditary Angioedema drug. Since the slump in the stock price is not backed by any substantial negative news, this anomaly may be used by investors for creating a position with medium to long term horizon. The stock has strong fundamentals and is likely to show positive growth as the company reports higher revenue and better margins in the coming quarters.
justiceforthemany
20/9/2017
21:18
Starting to think this one's a bit of a lemon. Pound goes up, shire goes down, dollar up, shire down. Company makes positive announcements, stock falls.
ruethewhirl
20/9/2017
20:59
Evening EI Dollar moving up against the £ on Yellen's speech tonight....FTSE futures looking good as well. Nobody seems to give a monkey's out here in Greece :-D
philanderer
20/9/2017
16:19
GBP Phil I reckon. My Tate holding is not looking too sweat ATM!, Tate a big USD earner
essentialinvestor
20/9/2017
14:18
Usual shareprice reaction. ;-) Shire nudged a touch lower after saying that it and its Japanese partner Shionogi saw positive results from a phase III clinical trial of Intuniv in adults with attention deficit hyperactivity disorder.
philanderer
Chat Pages: 97  96  95  94  93  92  91  90  89  88  87  86  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170926 03:52:47